Key Insights

Highlights

Success Rate

66% trial completion

Published Results

17 trials with published results (17%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

15.8%

16 terminated out of 101 trials

Success Rate

66.0%

-20.5% vs benchmark

Late-Stage Pipeline

9%

9 trials in Phase 3/4

Results Transparency

55%

17 of 31 completed with results

Key Signals

17 with results66% success16 terminated

Data Visualizations

Phase Distribution

90Total
Not Applicable (8)
Early P 1 (1)
P 1 (41)
P 2 (31)
P 3 (9)

Trial Status

Completed31
Recruiting22
Terminated16
Unknown14
Active Not Recruiting11
Not Yet Recruiting4

Trial Success Rate

66.0%

Benchmark: 86.5%

Based on 31 completed trials

Clinical Trials (101)

Showing 20 of 20 trials
NCT07006727Phase 1RecruitingPrimary

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT05882058Phase 2RecruitingPrimary

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05617963Phase 2Active Not RecruitingPrimary

Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

NCT06992609Phase 3RecruitingPrimary

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

NCT06586957Phase 1Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT06131840Phase 1Recruiting

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT07046923Phase 1Recruiting

A Study of LY4175408 in Participants With Advanced Cancer

NCT05616624Phase 1Active Not Recruiting

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

NCT04938817Phase 1RecruitingPrimary

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

NCT07015892Phase 3RecruitingPrimary

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial

NCT06957314Not ApplicableRecruiting

A Study of Hospital-at-Home for People Receiving Tarlatamab

NCT04585750Phase 1Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT05683977Active Not RecruitingPrimary

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.

NCT04665856Phase 3Active Not RecruitingPrimary

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

NCT05419076Phase 2Recruiting

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

NCT05620342Early Phase 1Recruiting

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

NCT07357532Phase 2Not Yet RecruitingPrimary

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

NCT06481813Not ApplicableRecruiting

Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients

NCT04199741Phase 1Recruiting

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

NCT07155200Phase 1Recruiting

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Scroll to load more

Research Network

Activity Timeline